LAB (STOCKS)
Standard BioTools Inc. Common Stock
$0.900000
+0.014700 (+1.66%)
Prev close: $0.885300
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Michael Egholm
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $345.29M
- Employees
- 818
- P/E (TTM)
- -4.47
- P/B (TTM)
- 0.81
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
2
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.05 | $-0.07 | +0.1207 | +170.72% |
|
Sep 2025 (Q3)
|
$-0.09 | $-0.06 | -0.0344 | -61.87% |
|
Jun 2025 (Q2)
|
$-0.09 | $-0.08 | -0.0092 | -11.39% |
|
Mar 2025 (Q1)
|
$-0.07 | $-0.08 | +0.0058 | +7.65% |
Financial Statements
| Revenues | $85.33M |
| Benefits Costs and Expenses | $182.03M |
| Cost Of Revenue | $42.79M |
| Costs And Expenses | $182.03M |
| Gross Profit | $42.54M |
| Operating Expenses | $152.79M |
| Selling, General, and Administrative Expenses | $109.86M |
| Research and Development | $25.99M |
| Other Operating Expenses | $16.94M |
| Operating Income/Loss | -$110.25M |
| Income/Loss From Continuing Operations After Tax | -$58.83M |
| Income/Loss From Continuing Operations Before Tax | -$96.70M |
| Income/Loss From Discontinued Operations Net Of Tax | -$16.07M |
| Income Tax Expense/Benefit | -$37.88M |
| Income Tax Expense/Benefit, Current | $892.00K |
| Income Tax Expense/Benefit, Deferred | -$38.77M |
| Net Income/Loss | -$74.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$74.90M |
| Net Income/Loss Available To Common Stockholders, Basic | -$74.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.20 |
| Diluted Earnings Per Share | -$0.20 |
| Basic Average Shares | 381,623,000 |
| Diluted Average Shares | 381,623,000 |
| Assets | $567.75M |
| Current Assets | $454.26M |
| Accounts Receivable | $13.43M |
| Inventory | $19.98M |
| Other Current Assets | $420.85M |
| Noncurrent Assets | $113.49M |
| Fixed Assets | $19.28M |
| Other Non-current Assets | $94.22M |
| Liabilities | $143.46M |
| Current Liabilities | $108.31M |
| Accounts Payable | $5.41M |
| Wages | $18.15M |
| Other Current Liabilities | $84.76M |
| Noncurrent Liabilities | $35.16M |
| Equity | $424.29M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $424.29M |
| Liabilities And Equity | $567.75M |
| Net Cash Flow From Operating Activities | -$74.34M |
| Net Cash Flow From Operating Activities, Continuing | -$74.34M |
| Net Cash Flow From Investing Activities | $27.41M |
| Net Cash Flow From Investing Activities, Continuing | $27.41M |
| Net Cash Flow From Financing Activities | $570.00K |
| Net Cash Flow From Financing Activities, Continuing | $570.00K |
| Exchange Gains/Losses | $842.00K |
| Net Cash Flow | -$45.52M |
| Net Cash Flow, Continuing | -$46.36M |
| Comprehensive Income/Loss | -$77.61M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$77.61M |
| Other Comprehensive Income/Loss | -$77.61M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.72M |